Can-Fite Biopharma Ltd Sponsore CANF

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
38/100
Developing

Ranked against 712 peers in Biotechnology

About Can-Fite Biopharma Ltd Sponsore

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of … Full CANF analysis →

Key strengths

  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.90), suggesting sticky customer base.

Key risks

  • ROIC Below WACC or Peers ROIC at 16.8th percentile suggests inefficient capital deployment.
  • Elevated Debt Risk Debt serviceability is weak (score 0.17), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
42
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where CANF ranks in Biotechnology

Can-Fite Biopharma Ltd Sponsore ranks #394 of 713 scored companies in Biotechnology by moat score — the top 55%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
390 Xenon Pharmaceuticals Inc. XENE 38/100 Developing
391 Aptorum Group Limited APM 38/100 Developing
392 Dogwood Therapeutics, Inc. DWTX 38/100 Developing
393 Jaguar Health, Inc. JAGX 38/100 Developing
394 Can-Fite Biopharma Ltd Sponsore CANF 38/100 Developing
395 Compass Therapeutics, Inc. CMPX 38/100 Developing
396 Lexaria Bioscience Corp. LEXXW 38/100 Developing
397 Abivax SA ABVX 38/100 Developing
398 Cibus, Inc. CBUS 38/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How CANF scores on the Corporate Default defenses

Pricing Power

Score 42 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 29 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 54 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 28 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 26 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 51 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding CANF's moat

What is Can-Fite Biopharma Ltd Sponsore's moat score?

Can-Fite Biopharma Ltd Sponsore (CANF) scores 38 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #394 of 713 scored companies in Biotechnology, the top 55%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Customer Stickiness (54/100) and its weakest is Resilience (26/100).

How does Can-Fite Biopharma Ltd Sponsore compare with other Biotechnology companies?

Can-Fite Biopharma Ltd Sponsore ranks #394 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Jaguar Health, Inc. (JAGX) at 38 just above it and Compass Therapeutics, Inc. (CMPX) at 38 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Can-Fite Biopharma Ltd Sponsore scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Can-Fite Biopharma Ltd Sponsore?

The Corporate Default template measures 6 defenses, and CANF scores: Pricing Power (42), Cost Advantage (29), Customer Stickiness (54), Capital Efficiency (28), Resilience (26), Scale & Market Position (51). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000